没血色
发表于 2025-3-25 04:17:37
http://reply.papertrans.cn/47/4671/467020/467020_21.png
建筑师
发表于 2025-3-25 09:56:36
http://reply.papertrans.cn/47/4671/467020/467020_22.png
Inkling
发表于 2025-3-25 13:12:36
http://reply.papertrans.cn/47/4671/467020/467020_23.png
carotenoids
发表于 2025-3-25 17:46:58
http://reply.papertrans.cn/47/4671/467020/467020_24.png
pus840
发表于 2025-3-25 21:00:33
http://reply.papertrans.cn/47/4671/467020/467020_25.png
恃强凌弱
发表于 2025-3-26 00:38:59
Bispecific and Biparatopic Antibody Drug Conjugates,in the early 1900’s the concept of a “magic bullet”, an ideal therapeutic that would specifically target a disease-causing agent without causing harm to the body. This concept still underpins the overarching goal of biopharmaceutical development today: to produce drugs that have a broad therapeutic
irreparable
发表于 2025-3-26 06:01:37
http://reply.papertrans.cn/47/4671/467020/467020_27.png
xanthelasma
发表于 2025-3-26 11:47:27
Antibody-Drug Conjugates: Targeting the Tumor Microenvironment,th the aim to increase anti-cancer activity and spare normal tissues from undesired toxicity. Until recently, most ADC development activities have focused on the use of monoclonal antibodies, capable of selective binding and internalization into the target tumor cells. However, in principle, it woul
compassion
发表于 2025-3-26 15:25:14
Next Horizons: ADCs Beyond Oncology,eyond oncology. The key variables for oncology ADCs in terms of the targeted cell type, targeting strategy, and payload are often clearer while the corresponding elements for non-oncology indications are more complex. Challenges in designing such non-oncology ADCs include selecting the targeting cel
arboretum
发表于 2025-3-26 17:31:04
http://reply.papertrans.cn/47/4671/467020/467020_30.png